BidaskClub downgraded shares of Amicus Therapeutics (NASDAQ:FOLD) from a hold rating to a sell rating in a report published on Thursday morning.
Other analysts have also issued research reports about the company. Chardan Capital boosted their price target on Amicus Therapeutics from $12.50 to $17.50 and gave the company a buy rating in a report on Thursday, August 10th. Robert W. Baird reissued an outperform rating and set a $18.00 price target (up previously from $16.00) on shares of Amicus Therapeutics in a report on Wednesday, October 4th. J P Morgan Chase & Co reaffirmed an overweight rating on shares of Amicus Therapeutics in a research note on Wednesday, October 4th. Cowen reaffirmed a buy rating and issued a $16.00 price objective on shares of Amicus Therapeutics in a research note on Monday, August 14th. Finally, Zacks Investment Research lowered Amicus Therapeutics from a buy rating to a hold rating in a research note on Thursday, October 12th. One equities research analyst has rated the stock with a sell rating, three have issued a hold rating and six have issued a buy rating to the company. The company currently has a consensus rating of Buy and an average price target of $17.81.
Amicus Therapeutics (NASDAQ FOLD) opened at $13.27 on Thursday. The company has a debt-to-equity ratio of 0.39, a quick ratio of 6.22 and a current ratio of 6.32. Amicus Therapeutics has a one year low of $4.41 and a one year high of $16.60.
In related news, CEO John F. Crowley sold 47,213 shares of the stock in a transaction that occurred on Monday, December 4th. The stock was sold at an average price of $13.61, for a total value of $642,568.93. Following the transaction, the chief executive officer now owns 375,214 shares of the company’s stock, valued at $5,106,662.54. The sale was disclosed in a legal filing with the SEC, which can be accessed through the SEC website. Also, insider Jay Barth sold 5,000 shares of the stock in a transaction that occurred on Friday, December 1st. The stock was sold at an average price of $13.59, for a total value of $67,950.00. Following the completion of the transaction, the insider now directly owns 69,184 shares in the company, valued at approximately $940,210.56. The disclosure for this sale can be found here. Over the last 90 days, insiders have sold 680,437 shares of company stock worth $9,734,522. Company insiders own 3.40% of the company’s stock.
A number of hedge funds and other institutional investors have recently made changes to their positions in FOLD. Sage Capital Advisors llc acquired a new stake in shares of Amicus Therapeutics in the 3rd quarter worth $154,000. GSA Capital Partners LLP acquired a new stake in shares of Amicus Therapeutics in the 3rd quarter worth $309,000. Iguana Healthcare Management LLC acquired a new stake in shares of Amicus Therapeutics in the 3rd quarter worth $905,000. Sterling Capital Management LLC acquired a new stake in shares of Amicus Therapeutics in the 3rd quarter worth $218,000. Finally, Neuberger Berman Group LLC acquired a new stake in shares of Amicus Therapeutics in the 3rd quarter worth $196,000.
Amicus Therapeutics Company Profile
Amicus Therapeutics, Inc is a biotechnology company. The Company is engaged in the discovery, development and commercialization of a set of treatments for patients living with devastating rare and orphan diseases. Its lead product, migalastat HCl is a small molecule that can be used as a monotherapy and in combination with enzyme replacement therapy (ERT) for Fabry disease.
Receive News & Ratings for Amicus Therapeutics Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Amicus Therapeutics Inc. and related companies with MarketBeat.com's FREE daily email newsletter.